Pittsburgh Compound-B (PiB) binds amyloid β-protein protofibrils

Area of Science:

• Neuroscience
• Biochemistry
• Medical Imaging

Background:

• Alzheimer's disease (AD) pathology involves amyloid-beta (Aβ) plaques and tau tangles.
• Positron emission tomography (PET) with Pittsburgh Compound-B (PiB) is used to visualize Aβ in AD brains.
• Emerging evidence suggests Aβ oligomers and protofibrils are key pathogenic species in AD.

Purpose of the Study:

• To determine if PiB binds to Aβ40 and Aβ42 oligomers and protofibrils.
• To assess the potential of PiB for detecting early-stage Aβ pathologies.

Main Methods:

• In vitro experiments were conducted using synthesized Aβ40 and Aβ42.
• Binding affinities of PiB to Aβ40 and Aβ42 fibrils, protofibrils, and oligomers were measured.
• Comparative analysis of PiB binding across different Aβ species and forms.

Main Results:

• PiB demonstrated strong binding to Aβ42 fibrils.
• Significant binding was observed for PiB with Aβ42 protofibrils.
• Weaker binding of PiB was noted for Aβ42 oligomers.
• PiB also bound to Aβ40 fibrils, but with substantially lower affinity to Aβ40 protofibrils and oligomers compared to Aβ42.

Conclusions:

• PiB exhibits varying binding affinities for different forms of amyloid-beta.
• The compound shows notable binding to Aβ42 protofibrils, suggesting potential for detecting these species.
• Differential binding characteristics of PiB for Aβ40 and Aβ42 species warrant further investigation for diagnostic applications.